Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)

BACKGROUND: Lymph node dissection is a therapeutic option for prostate cancer patients with a high risk of- or proven lymph node metastases. Radioguided surgery after intravenous injection of [(99m)Tc]Tc-PSMA could improve the selectivity of lymph node dissection. The aim of this project was to deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Aalbersberg, Else A., van Andel, Lotte, Geluk-Jonker, Martine M., Beijnen, Jos H., Stokkel, Marcel P. M., Hendrikx, Jeroen J. M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195502/
https://www.ncbi.nlm.nih.gov/pubmed/32358637
http://dx.doi.org/10.1186/s41181-020-00095-9
Descripción
Sumario:BACKGROUND: Lymph node dissection is a therapeutic option for prostate cancer patients with a high risk of- or proven lymph node metastases. Radioguided surgery after intravenous injection of [(99m)Tc]Tc-PSMA could improve the selectivity of lymph node dissection. The aim of this project was to develop an automated synthesis method for [(99m)Tc]Tc-PSMA, using the disposables and chemicals used at our institute for [(68)Ga]Ga-PSMA labeling. Furthermore, quality control procedures and validation results of the automated production of [(99m)Tc]Tc-PSMA conform cGMP and cGRPP are presented. METHODS: [(99m)Tc]Tc-PSMA is produced fully automatic with a Scintomics synthesis module. Quality control procedures are described and performed for: activity, labeling yield, visual inspection, pH measurement, sterility and endotoxin determination, radionuclide purity, radiochemical purity ((99m)Tc-colloids, unbound [(99m)Tc]pertechnetate, and other impurities), and HEPES content. Three batches of [(99m)Tc]Tc-PSMA were prepared on three separate days for validation and stability testing at 0, 4, 6, and 24 h. RESULTS: [(99m)Tc]Tc-PSMA can be successfully manufactured automatically within a [(68)Ga]Ga-PSMA workflow with the addition of only [(99m)Tc]pertechnetate and stannous chloride. The radiochemical purity after production was highly reproducible (96.3%, 97.6%, and 98.2%) and remained > 90% (required for patient administration) up to 6 h later. CONCLUSION: A fully automated labeling procedure with corresponding quality control methods for production of [(99m)Tc]Tc-PSMA is presented, which is validated according to cGMP and cGRPP guidelines and can be implemented in a GMP environment. The produced [(99m)Tc]Tc-PSMA is stable for up to 6 h. The presented procedure is almost identical to the automated production of [(68)Ga]Ga-PSMA and can therefore be implemented expediently if a workflow for [(68)Ga]Ga-PSMA is already in place.

Ejemplares similares